Outcomes with FOLFIRINOX for Borderline Resectable and Locally Unresectable Pancreatic Cancer

BACKGROUND: Trials examining FOLFIRINOX in metastatic pancreatic cancer demonstrate higher response rates compared to gemcitabine-based regimens. There is currently limited experience with neoadjuvant FOLFIRINOX in pancreatic cancer. METHODS: Retrospective review of outcomes of patients with borderl...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Boone, Brian A., Steve, Jennifer, Krasinskas, Alyssa M., Zureikat, Amer H., Lembersky, Barry C., Gibson, Michael K., Stoller, Ronald, Zeh, Herbert J., Bahary, Nathan
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3816713/
https://ncbi.nlm.nih.gov/pubmed/23955427
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jso.23392
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados